Amgen News

IA could write this article the usual way -- byA showing you how to turn your thousands into millionsA through investments in solid, well-known companies.

Wesely-Thomas Enterprises CEO Carl Wesely takes a look around an operating room at Los Robles Hospital & Medical Center in Thousand Oaks on Friday.

Although Amgen Inc.'s Phase III Vectibix-Folfox combination met its main goal - to improve progression-free survival in patients with advanced colorectal cancer in the first-line setting - it missed its secondary endpoint of overall survival, the company reported Thursday.

Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix administered in combination with FOLFOX as a first-line treatment of metastatic colorectal cancer failed to meet a secondary endpoint of overall survival.

Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co.

Hawaii is one of several states suing biotechnology behemoth Amgen Inc. for allegedly giving kickbacks to medical providers to help boost sales of the anemia drug Aranesp.

Amgen Inc., the world's largest biotechnology company, is being sued by Indiana, New York and 13 other states following an investigation into a national kickback scheme to boost drug sales, New York Attorney General Andrew Cuomo said.

Stock-PR.com, a division of Crown Equity Holdings Inc. tracks stocks daily and is pleased to offer its hot stock alerts.

Several state attorneys general allege the U.S. biotechnology firm Amgen Inc. has engaged in illegal kickbacks to help sales of its anemia drug Aranesp.

Amgen Inc. on Friday was sued by 14 states and the District of Columbia, which accuse the Thousand Oaks biotech of offering kickbacks to medical providers to boost sales of its troubled anemia drug Aranesp.

Amgen today announced the publication of results from TREAT , a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease not on dialysis, moderate anemia and type-2 diabetes.

A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.

Biotechnology behemoth Amgen Inc. is being sued by 15 states alleging a scheme of kickbacks to medical providers to help boost sales of the anemia drug Aranesp.

Watching insiders is like participating in a weeks-long stakeout. You expect something to happen, but you don't know what.

The major indexes rocked Thursday's session with gains across the board. The Dow closed up 1.3%, the S&P added 1.1% and the Nasdaq moved higher by 0.7%. Here are Thursday's winners and losers: Winners New York Times Co.

Guidance Analysts are looking for EPS of $1.27 on revenue of $3.79B. The consensus range is $1.20-$1.34 for EPS, and $3.73B-$3.88B for revenue, according to First Call.

Genzyme 's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, it's still dealing with the aftermath.

U.S. Market Stocks started the day higher after a fresh round of before-market earnings reports, but gave back their gains this afternoon.

Amgen Inc., the worlda s largest biotechnology company, said profit increased 24 percent on cost cuts.

Amgen Inc., the worlda s largest biotechnology company, said third-quarter profit rose 24 percent as sales of most of its core drugs beat analystsa estimates.